Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Investigating Potential Drug-Drug Interactions from Greek e-Prescription Data

Author(s): Panagiotis-Nikolaos Lalagkas, Georgios Poulentzas, Lampros Tsiolis, Eleftherios Berberoglou, Dimitra Hadjipavlou-Litina, Antonios Douros, Christos Kontogiorgis* and Theodoros Constantinides

Volume 17, Issue 2, 2022

Published on: 15 March, 2022

Page: [114 - 120] Pages: 7

DOI: 10.2174/1574886316666210816115811

Price: $65

Abstract

Background: The prevalence of potential drug-drug interactions (pDDIs) is indicative of the prevalence of actual drug-drug interactions and prescription quality. However, they are significantly understudied in Greece.

Objective: The objective of the study was to determine the prevalence of pDDIs among outpatients and identify factors associated with their occurrence.

Methods: Anonymous e-prescription data between 2012 and 2017 were obtained from community pharmacies in Thessaloniki, Greece. Patients taking more than one medication for at least three months were included. pDDIs were identified and categorized depending on their clinical significance using Drug Interactions Checker. Crude and adjusted odds ratios (ORs) with accompanying 95% confidence intervals (CIs) of risk factors of pDDIs occurrence were identified using multivariable logistic regression.

Results: During the study period, 6,000 anonymous e-prescriptions (1,000 per year) satisfying the inclusion criteria were collected. The overall prevalence of major pDDIs was 17.4% (63.0% for moderate pDDIs). The most common major pDDIs were between amlodipine and simvastatin (22.8% of major interactions), followed by clopidogrel and omeprazole (6.4% of major interactions). Polypharmacy (≥5 concomitantly received medications) was associated with an increased risk of major pDDIs (adjusted OR, 5.72; 95% CI, 4.87-6.72); no associations were observed regarding age, sex, and number of prescribing physicians.

Conclusion: The prevalence of pDDIs in this study was higher than previously reported in other European countries, with polypharmacy being a potential risk factor. Those results argue for a need for improvement in the area of prescribing in Greece.

Keywords: Drug-drug interactions, potential drug-drug interactions major interactions, polypharmacy, community pharmacies, outpatients, prescription medicines, chronic diseases’ treatment.

« Previous Next »
Graphical Abstract

[1]
Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 2011; 9(6): 364-77.
[http://dx.doi.org/10.1016/j.amjopharm.2011.10.004] [PMID: 22078863]
[2]
Day RO, Snowden L, McLachlan AJ. Life-threatening drug interactions: what the physician needs to know. Intern Med J 2017; 47(5): 501-12.
[http://dx.doi.org/10.1111/imj.13404] [PMID: 28503886]
[3]
Mannheimer B, Ulfvarson J, Eklöf S, et al. Drug-related problems and pharmacotherapeutic advisory intervention at a medicine clinic. Eur J Clin Pharmacol 2006; 62(12): 1075-81.
[http://dx.doi.org/10.1007/s00228-006-0214-z] [PMID: 17066294]
[4]
Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2014; 23(5): 489-97.
[http://dx.doi.org/10.1002/pds.3592] [PMID: 24616171]
[5]
Fokter N, Možina M, Brvar M. Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments. Wien Klin Wochenschr 2010; 122(3-4): 81-8.
[http://dx.doi.org/10.1007/s00508-009-1251-2] [PMID: 20213374]
[6]
Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: Updating the cost-of-illness model. J Ameri Pharma Associ 2001; 41(2): 192-9.
[7]
Fastbom J, Johnell K. National indicators for quality of drug therapy in older persons: the Swedish experience from the first 10 years. Drugs Aging 2015; 32(3): 189-99.
[http://dx.doi.org/10.1007/s40266-015-0242-4] [PMID: 25673123]
[8]
Onder G, Bonassi S, Abbatecola AM, et al. High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). J Gerontol A Biol Sci Med Sci 2014; 69(4): 430-7.
[http://dx.doi.org/10.1093/gerona/glt118] [PMID: 23913935]
[9]
Spencer R, Bell B, Avery AJ, Gookey G, Campbell SM. Identification of an updated set of prescribing- safety indicators for GPs. Br J Gen Pract 2014; 64(621): e181-90.
[http://dx.doi.org/10.3399/bjgp14X677806] [PMID: 24686882]
[10]
Nobili A, Pasina L, Tettamanti M, et al. Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database. J Clin Pharm Ther 2009; 34(4): 377-86.
[http://dx.doi.org/10.1111/j.1365-2710.2009.01021.x] [PMID: 19583670]
[11]
Jazbar J, Locatelli I, Horvat N, Kos M. Clinically relevant potential drug-drug interactions among outpatients: A nationwide database study. Res Social Adm Pharm 2018; 14(6): 572-80.
[http://dx.doi.org/10.1016/j.sapharm.2017.07.004] [PMID: 28716467]
[12]
Teramura-Grönblad M, Raivio M, Savikko N, et al. Potentially severe drug-drug interactions among older people and associations in assisted living facilities in Finland: a cross-sectional study. Scand J Prim Health Care 2016; 34(3): 250-7.
[http://dx.doi.org/10.1080/02813432.2016.1207142] [PMID: 27428445]
[13]
Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 2007; 30(10): 911-8.
[http://dx.doi.org/10.2165/00002018-200730100-00009] [PMID: 17867728]
[14]
Andersson ML, Böttiger Y, Kockum H, Eiermann B. High prevalence of drug-drug interactions in primary health care is caused by prescriptions from other healthcare units. Basic Clin Pharmacol Toxicol 2018; 122(5): 512-6.
[http://dx.doi.org/10.1111/bcpt.12939] [PMID: 29143454]
[15]
Economou C, Kaitelidou D, Karanikolos M, Maresso A. Greece: health system review. Health Syst Transit 2017; 19(5): 1-166.
[PMID: 29972131]
[16]
Pangalos G, Sfyroeras V, Pagkalos I. E-prescription as a tool for improving services and the financial viability of healthcare systems: the case of the Greek national e-prescription system. Int J Electron Healthc 2014; 7(4): 301-14.
[http://dx.doi.org/10.1504/IJEH.2014.064331] [PMID: 25161106]
[17]
Chatsisvili A, Sapounidis I, Pavlidou G, et al. Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharm World Sci 2010; 32(2): 187-93.
[http://dx.doi.org/10.1007/s11096-010-9365-1] [PMID: 20077137]
[18]
Hellenic Statistical Authority. Pharmacies, by geographical department and prefecture, and a set of drugstores. 2019.
[19]
Rinner C, Grossmann W, Sauter SK, Wolzt M, Gall W. Effects of shared electronic health record systems on drug-drug interaction and duplication warning detection. BioMed Res In 2015; 2015: 380497.
[http://dx.doi.org/10.1155/2015/380497]
[20]
Drug Interactions Checker - For Drugs, Food & Alcohol. 2014. Available from: http://www.drugs.com/drug_interactions.html.
[21]
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17(1): 230.
[http://dx.doi.org/10.1186/s12877-017-0621-2] [PMID: 29017448]
[22]
Holm J, Eiermann B, Eliasson E, Mannheimer B. A limited number of prescribed drugs account for the great majority of drug- drug interactions. Eur J Clin Pharmacol 2014; 70(11): 1375-83.
[http://dx.doi.org/10.1007/s00228-014-1745-3] [PMID: 25190295]
[23]
Buurma H, De Smet PAGM, Egberts ACG. Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. Drug Saf 2006; 29(8): 723-32.
[http://dx.doi.org/10.2165/00002018-200629080-00009] [PMID: 16872246]
[24]
Toivo TM, Mikkola JAV, Laine K, Airaksinen M. Identifying high risk medications causing potential drug-drug interactions in outpatients: A prescription database study based on an online surveillance system. Res Social Adm Pharm 2016; 12(4): 559-68.
[http://dx.doi.org/10.1016/j.sapharm.2015.09.004] [PMID: 26459026]
[25]
Roughead EE, Kalisch LM, Barratt JD, Gilbert AL. Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol 2010; 70(2): 252-7.
[http://dx.doi.org/10.1111/j.1365-2125.2010.03694.x] [PMID: 20653678]
[26]
Metge CJ, Hendricksen C, Maine L. Consumer attitudes, behaviors, and perceptions about pharmacies, pharmacists, and pharmaceutical care. J Amer Pharm Assoc 1996; 38(1): 37-47.
[27]
Charami MT. Application of CRM in the case of Greek pharmaceutical marketing: A case study of a community pharmacy in a Greek rural provinces Thessaloniki 2010.
[28]
Andersson ML, Böttiger Y, Lindh JD, Wettermark B, Eiermann B. Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care. Eur J Clin Pharmacol 2013; 69(3): 565-71.
[http://dx.doi.org/10.1007/s00228-012-1338-y] [PMID: 22752671]
[29]
Bertsche T, Pfaff J, Schiller P, et al. Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med 2010; 36(4): 665-72.
[http://dx.doi.org/10.1007/s00134-010-1778-8] [PMID: 20143221]
[30]
Arnold RJG, Tang J, Schrecker J, Hild C. Impact of definitive drug-drug interaction testing on medication management and patient care. Drugs Real World Outcomes 2018; 5(4): 217-24.
[http://dx.doi.org/10.1007/s40801-018-0143-z] [PMID: 30298445]
[31]
Bista D, Saha A, Mishra P, Palaian S, Shankar PR. Impact of educational intervention on the pattern and incidence of potential drug-drug interactions in Nepal. Pharm Pract (Granada) 2009; 7(4): 242-7.
[http://dx.doi.org/10.4321/S1886-36552009000400008] [PMID: 25136400]
[32]
Raschi E, Piccinni C, Signoretta V, et al. Clinically important drug-drug interactions in poly-treated elderly outpatients: a campaign to improve appropriateness in general practice. Br J Clin Pharmacol 2015; 80(6): 1411-20.
[http://dx.doi.org/10.1111/bcp.12754] [PMID: 26303150]
[33]
Ko Y, Malone DC, Skrepnek GH, et al. Prescribers’ knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf 2008; 31(6): 525-36.
[http://dx.doi.org/10.2165/00002018-200831060-00007] [PMID: 18484786]
[34]
Peabody J, Acelajado MC, Robert T, et al. Drug-drug interaction assessment and identification in the primary care setting. J Clin Med Res 2018; 10(11): 806-14.
[http://dx.doi.org/10.14740/jocmr3557w] [PMID: 30344815]

Rights & Permissions Print Cite
Article Metrics
31
1
© 2025 Bentham Science Publishers | Privacy Policy